AAHKS临床研究奖:骨内区域双氯芬酸用于全膝关节置换术后疼痛管理
一项前瞻性双盲随机对照试验纳入46例初次全膝关节置换术患者,比较骨内区域给药双氯芬酸与静脉双氯芬酸的术后镇痛效果。结果显示骨内区域给药组在术后早期疼痛评分更低、阿片类药物消耗更少,且恢复质量、行走和睡眠影响、膝关节功能评分及患者满意度更优。
要点
- 骨内区域双氯芬酸组在术后1、12、24小时及术后第1天疼痛评分均低于静脉给药组。
- 骨内区域双氯芬酸组在术后第0至3天阿片类药物消耗量(吗啡毫克当量)均少于静脉给药组。
- 骨内区域双氯芬酸组恢复质量-15评分、术后第1天行走和睡眠影响、术后2周膝关节功能评分及患者满意度均更优。
核心结论
- 骨内区域给予双氯芬酸可增强全膝关节置换术后早期疼痛缓解并减少阿片类药物消耗,同时改善早期膝关节功能和患者满意度。
研究设计与样本
- 前瞻性、双盲、随机对照试验,纳入46例初次全膝关节置换术患者,每组23例。
主要发现
- 骨内区域双氯芬酸组视觉模拟疼痛评分(毫米,[95%置信区间])在术后1小时为21.2[16.3, 31.4] vs 静脉组40.2[30.8, 50.8],P=0.007;12小时为18.2[12.1, 25.6] vs 36.5[27.6, 46.6],P=0.002;24小时为21.3[14.6, 29.2] vs 39.5[30.2, 50],P=0.003;术后第1天为23.5[17.8, 30] vs 35.4[28.3, 43.3],P=0.01。
- 骨内区域双氯芬酸组阿片类药物消耗量(吗啡毫克当量均值,毫克)在术后第0天为20.2[12.4, 28.0] vs 静脉组45.3[37.7, 53.0];术后第1天为27.7[19.2, 34.8] vs 43[35.4, 50.6];术后第2天为32.1[24.3, 39.9] vs 51.5[43.9, 59.1];术后第3天为27.4[19.6, 35.2] vs 41.3[33.7, 48.9]。
- 骨内区域双氯芬酸组恢复质量-15评分更优(P=0.04),术后第1天行走影响(P=0.001)和睡眠影响(P=0.003)更优,术后2周膝关节损伤与骨关节炎结局评分(KOOS-JR)更优(P=0.03),患者满意度更优(P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective postoperative pain management is important following primary total knee arthroplasty (TKA). Intraosseous regional administration (IORA) of antibiotics in TKA results in higher local tissue concentrations, potentially improving efficacy. We investigated using IORA diclofenac to improve postoperative pain management in TKA compared to intravenous (IV) diclofenac. METHODS: There were 46 primary TKA patients (23 per group) enrolled in a prospective, double-blinded, randomized controlled trial. The intervention group received 75 mg IORA diclofenac and an IV normal saline placebo. The control group received 75 mg IV diclofenac and an intraosseous normal saline placebo. Pain levels were measured on a visual analog scale for pain (VAS-P) until postoperative day (POD) seven. The secondary outcomes included opioid consumption, quality of recovery-15, impact of pain on walking and sleep, length of admission, patient satisfaction, the Knee Injury and Osteoarthritis Outcome Score for Joint Replacements, and Oxford Knee Score. RESULTS: Intervention group visual analog scale for pain scores (mm, [95% confidence interval]) were lower at one (21.2 [16.3, 31.4] versus 40.2 [30.8 to 50.8]; P = 0.007), 12 (18.2 [12.1 to 25.6] versus 36.5 [27.6 to 46.6]; P = 0.002), and 24 hours (21.3 [14.6 to 29.2] versus 39.5 [30.2 to 50]; P = 0.003), and POD one (23.5 [17.8 to 30] versus 35.4 [28.3 to 43.3]; P = 0.01). The intervention group consumed fewer opioids (mean morphine milligram equivalent in mg) from POD zero (20.2 [12.4 to 28.0] versus 45.3 [37.7 to 53.0]), POD one (27.7 [19.2 to 34.8] versus 43 [35.4 to 50.6]), POD two (32.1 [24.3 to 39.9] versus 51.5 [43.9 to 59.1]), and POD three (27.4 [19.6 to 35.2] versus 41.3 [33.7 to 48.9]). Moreover, they demonstrated better quality of recovery-15 scores (P = 0.04), POD one walking (P = 0.001) and sleeping (P = 0.003), Knee Injury and Osteoarthritis Outcome Score for Joint Replacements scores (P = 0.03), and patient satisfaction (P = 0.04) at 2 weeks postsurgery. CONCLUSIONS: The IORA diclofenac provided enhanced early postoperative pain relief and reduced opioid consumption, with better early knee function and patient satisfaction following TKA.
引用
- Ng JS, van der Werf B, Nicholson L, et al. The AAHKS Clinical Research Award: Intraosseous Regional Diclofenac for Postoperative Pain Management in Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40349862. doi:10.1016/j.arth.2025.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。